Retrospective research for efficacy and safety of modified FOLFIRINOX as 1st line therapy for advanced pancreatic cancer

被引：0
|
作者：
Dazai, Masayoshi [1 ,2 ]
Suzuki, Kazuharu [1 ]
Nakajima, Masahito [1 ]
Yagisawa, Masataka [1 ]
Kobayashi, Yoshimitu [1 ]
Kudo, Taiki [1 ]
Takahashi, Kazuhiro [1 ]
Sogabe, Susumu [1 ]
Oda, Hisashi [1 ]
Miyagishima, Takuto [1 ]
机构：
[1] Kushiro Rosai Hosp, Dept Internal Med, Kushiro, Hokkaido, Japan
[2] NTT East Sapporo Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-8-9
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience
    Mahaseth, Hemchandra
    Kauh, John S.
    Brutcher, Edith
    Hawk, Natalyn Nicole
    Kim, Sungjin
    Chen, Zhengjia
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study
    Ye, Liu-Fang
    Ren, Chao
    Bai, Long
    Liang, Jie-Ying
    Hu, Ming-Tao
    Yang, Hui
    Wang, Zhi-Qiang
    Wang, Feng-Hua
    Xu, Rui-Hua
    Li, Yu-Hong
    Wang, De-Shen
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 836 - 845
  • [3] Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study
    Liu-Fang Ye
    Chao Ren
    Long Bai
    Jie-Ying Liang
    Ming-Tao Hu
    Hui Yang
    Zhi-Qiang Wang
    Feng-Hua Wang
    Rui-Hua Xu
    Yu-Hong Li
    De-Shen Wang
    Investigational New Drugs, 2021, 39 : 836 - 845
  • [4] Safety and efficacy of modified FOLFIRINOX in patients with metastatic pancreatic cancer
    Watanabe, Kazuo
    Takahashi, Hideaki
    Umemoto, Kumiko
    Okuyama, Hiroyuki
    Hashimoto, Yusuke
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Okusaka, Takuji
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2015, 26 : 88 - 88
  • [5] Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
    Fumet, Jean-David
    Vincent, Julie
    Bengrine, Leila
    Hennequin, Audrey
    Granconato, Laura
    Palmier, Remi
    Ghiringhelli, Francois
    ANTICANCER RESEARCH, 2020, 40 (07) : 4011 - 4015
  • [6] THE EFFICACY AND SAFETY OF MODIFIED FOLFIRINOX FOR UNRESECTABLE ADVANCED PANCREATIC CANCER IN ELDERLY VERSUS YOUNG PATIENTS: A MULTICENTER RETROSPECTIVE COHORT STUDY
    Tezuka, Ryuichi
    Iwashita, Takuji
    Uemura, Shinya
    Senju, Akihiko
    Yoshida, Kensaku
    Maruta, Akinori
    Iwata, Keisuke
    Shimizu, Masahito
    GASTROENTEROLOGY, 2023, 164 (06) : S603 - S603
  • [7] The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort study
    Tezuka, Ryuichi
    Iwashita, Takuji
    Uemura, Shinya
    Senju, Akihiko
    Yoshida, Kensaku
    Maruta, Akinori
    Iwata, Keisuke
    Shimizu, Masahito
    PANCREATOLOGY, 2022, 22 (08) : 1134 - 1140
  • [8] The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
    Wang, Zhi-Qiang
    Zhang, Fei
    Deng, Ting
    Zhang, Le
    Feng, Fen
    Wang, Feng-Hua
    Wang, Wei
    Wang, De-Shen
    Luo, Hui-Yan
    Xu, Rui-Hua
    Ba, Yi
    Li, Yu-Hong
    CANCER COMMUNICATIONS, 2019, 39
  • [9] Phase 2 study of 1st-line modified FOLFIRINOX in unresectable advanced pancreatic cancer: Multicenter prospective study
    Yoshida, Kensaku
    Iwashita, Takuji
    Uemura, Shinya
    Maruta, Akinori
    Shimizu, Masahito
    Iwata, Keisuke
    Mukai, Tsuyoshi
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2
    Shaverdashvili, K.
    Reyes, V.
    Wang, H.
    Mehta, D.
    Marsh, C.
    Waas, J. K.
    VanderWeele, R. A.
    Peracha, S. M.
    Liang, H.
    Gerber, D. E.
    Dowell, J.
    Villaruz, L. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S322 - S322
12345